

## **Notes for December 2012 Court Case Errata – docetaxel and risedronate**

Following a court order on 6 December 2012 amendments are required to the prices published for 1 December 2012 for brands containing the drug risedronic acid for oral administration and brands containing the drug docetaxel for administration by injection.

The corrected prices for risedronate listings are set out in the erratum published with this note for the 1 December 2012 **Schedule of Pharmaceutical Benefits**.

The corrected prices for docetaxel listings are set out in the erratum published with this note for the 1 December 2012 **Schedule of Pharmaceutical Benefits - Efficient Funding of Chemotherapy Section 100 Arrangements Supplement**.

The subsidies for claims made for PBS and RPBS supplies to patients from 1 December 2012 onward will accord with the amended prices set out in the errata. Claims submitted by pharmacists and other PBS/RPBS suppliers for risedronate and docetaxel supplies will be correctly paid from 1 January 2013. All claims submitted from 1 December 2012 to 31 December 2012 will be retrospectively adjusted by the end of January 2013 to ensure that pharmacists and other PBS/RPBS suppliers are reimbursed based on the corrected prices set out in the errata published with this note.

The pbs.gov.au website will reflect the corrected prices for risedronate and docetaxel listings from 1 January 2013.

The 1 January 2013 hardcopy and pdf Schedule of Pharmaceutical Benefits will have an erratum for the corrected prices.